← All trials
NCT04899115
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 6, 2021
- Primary completion
- Aug 31, 2022
- Completion date
- Dec 31, 2022
- First posted
- May 24, 2021
- Last posted
- Sep 22, 2021
- Enrollment
- 18
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of MichiganLead sponsor
- University of MichiganSponsor investigator
- University of MichiganOverall official - principal investigator
- American Association for the Study of Liver DiseasesCollaborator
- American College of GastroenterologyCollaborator
- Vedanta Biosciences, Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.